GREENWICH LIFESCIENCES, INC. Increase (Decrease) in Employee Related Liabilities
GREENWICH LIFESCIENCES, INC. (GLSI) reported Increase (Decrease) in Employee Related Liabilities of -$219.42 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $4.70K.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$224.11K, a 2753.49% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $69.66K, a 740.21% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $123.98K, a 148.82% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in employee related liabilities for fiscal 2025 was $200.58K, a 430.26% increase from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in employee related liabilities for fiscal 2024 was $37.83K.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in employee related liabilities for fiscal 2023 was -$3.97K.
- GREENWICH LIFESCIENCES, INC. increase (decrease) in employee related liabilities for fiscal 2022 was -$122.27K, a 216.49% decline from fiscal 2021.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$219.42K 10-Q · filed 2026-08-11 | -$149.76K derived: sum of 3 quarters · filed 2026-08-11 | -$25.77K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$224.11K 10-Q · filed 2026-06-04 | -$154.45K derived: sum of 2 quarters · filed 2026-06-04 | -$30.47K derived: sum of 3 quarters · filed 2026-06-04 | -$31.98K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $69.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $193.64K derived: sum of 2 quarters · filed 2026-06-01 | $192.13K derived: sum of 3 quarters · filed 2026-08-11 | $200.58K 10-K · filed 2026-06-01 |
| 2025-09-30 | $123.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $122.47K derived: sum of 2 quarters · filed 2026-08-11 | $130.92K 10-Q · filed 2025-11-14 | $139.21K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.94K 10-Q · filed 2026-08-11 | $15.23K derived: sum of 3 quarters · filed 2026-08-11 | $65.06K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $8.45K 10-Q · filed 2026-06-04 | $16.74K derived: sum of 2 quarters · filed 2026-06-04 | $66.56K derived: sum of 3 quarters · filed 2026-06-04 | $41.33K derived: sum of 4 quarters · filed 2026-06-04 |
| 2024-12-31 | $8.29K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $58.12K derived: sum of 2 quarters · filed 2026-06-01 | $32.89K derived: sum of 3 quarters · filed 2026-06-01 | $37.83K 10-K · filed 2026-06-01 |
| 2024-09-30 | $49.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $24.60K derived: sum of 2 quarters · filed 2025-11-14 | $29.54K 10-Q · filed 2025-11-14 | $1.24K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$25.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$20.29K 10-Q · filed 2025-08-14 | -$48.59K derived: sum of 3 quarters · filed 2025-08-14 | $16.71K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $4.94K 10-Q · filed 2025-05-20 | -$23.36K derived: sum of 2 quarters · filed 2025-05-20 | $41.95K derived: sum of 3 quarters · filed 2025-05-20 | $28.30K derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | -$28.30K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $37.01K derived: sum of 2 quarters · filed 2025-04-15 | $23.36K derived: sum of 3 quarters · filed 2025-04-15 | -$3.97K 10-K · filed 2025-04-15 |
| 2023-09-30 | $65.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $51.66K derived: sum of 2 quarters · filed 2024-11-14 | $24.32K 10-Q · filed 2024-11-14 | $49.35K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$13.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$40.98K 10-Q · filed 2024-08-14 | -$15.95K derived: sum of 3 quarters · filed 2024-08-14 | -$7.21K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$27.33K 10-Q · filed 2024-05-20 | -$2.30K derived: sum of 2 quarters · filed 2024-05-20 | $6.44K derived: sum of 3 quarters · filed 2024-05-20 | -$5.59K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $25.03K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $33.77K derived: sum of 2 quarters · filed 2024-04-15 | $21.74K derived: sum of 3 quarters · filed 2024-04-15 | -$122.27K 10-K · filed 2024-04-15 |
| 2022-09-30 | $8.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | -$3.29K derived: sum of 2 quarters · filed 2023-10-19 | -$147.29K 10-Q · filed 2023-10-19 | -$142.24K derived: sum of 4 quarters · filed 2023-10-19 |
| 2022-06-30 | -$12.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$156.04K 10-Q · filed 2023-08-21 | -$150.99K derived: sum of 3 quarters · filed 2023-08-21 | -$16.73K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | -$144.00K 10-Q · filed 2023-05-22 | -$138.95K derived: sum of 2 quarters · filed 2023-05-22 | -$4.69K derived: sum of 3 quarters · filed 2023-05-22 | -$43.52K derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $5.05K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $139.31K derived: sum of 2 quarters · filed 2023-03-31 | $100.48K derived: sum of 3 quarters · filed 2023-03-31 | $104.96K 10-K · filed 2023-03-31 |
| 2021-09-30 | $134.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $95.43K derived: sum of 2 quarters · filed 2022-11-14 | $99.91K 10-Q · filed 2022-11-14 | $21.27K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$38.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$34.35K 10-Q · filed 2022-08-15 | -$112.99K derived: sum of 3 quarters · filed 2022-08-15 | -$55.38K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $4.48K 10-Q · filed 2022-05-20 | -$74.16K derived: sum of 2 quarters · filed 2022-05-20 | -$16.55K derived: sum of 3 quarters · filed 2022-05-20 | $729.00 derived: sum of 4 quarters · filed 2022-05-20 |
| 2020-12-31 | -$78.64K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$21.03K derived: sum of 2 quarters · filed 2022-03-21 | -$3.75K derived: sum of 3 quarters · filed 2022-03-21 | $47.74K 10-K · filed 2022-03-21 |
| 2020-09-30 | $57.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $74.89K derived: sum of 2 quarters · filed 2021-11-15 | $126.38K 10-Q · filed 2021-11-15 | -$34.16K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $17.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $68.78K 10-Q · filed 2021-08-13 | -$91.76K derived: sum of 3 quarters · filed 2021-08-13 | |
| 2020-03-31 | $51.49K 10-Q · filed 2021-05-20 | -$109.05K derived: sum of 2 quarters · filed 2021-05-20 | ||
| 2019-12-31 | -$160.54K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$19.26K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $141.28K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |